Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | m4b34 | — |
received the third dose 10 days earlier than recommended/early dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 66-year-old female patient who received HAB (Twinrix) (batch number m4b34, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix (Patient received second dose on 24-NOV-2024). On 15-APR-2025, the patient received the 3rd dose of Twinrix. On 15-APR-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: received the third dose 10 days earlier than recommended/early dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-APR-2025 Reporter asked how to proceed with the schedule of Twinrix when the patient received the third dose 10 days earlier than recommended. The patient received third dose of Twinrix, earlier than the recommended interval, which led to shortening of vaccinations schedule.